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Background: We investigate the evolving molecular epidemiology of metallo-β-lactamase (MBL)-producing
Pseudomonas aeruginosa isolates collected in a 100 institution, nationwide surveillance study in Japan from 2004
to 2006.
Results: MBL-producers were detected in 23/996 isolates (2.3%) in 2004 and 21/992 (2.1%) in 2006. Antimicrobial
resistance (specifically, carbapenem resistance) rates between two periods did not differ significantly. MBL-producers
were more prevalent in urinary tract isolates. blaIMP-1 group was the most predominant (38 isolates, 80%), followed by 3
blaIMP-7, 2 blaIMP-11 group, and 1 blaVIM-1. All MBL genes were identified in 16 different class 1 integrons, most of which
were novel to INTEGRALL database. A total of 17 isolates of sequence type (ST) 235, a recognized worldwide
drug-resistant lineage, were distributed in 5 geographic regions across Japan. ST235 isolates included a sublineage
associated with In113-like integron. ST357 was identified in 14 isolates, 9 of which harboring a sole blaIMP-1 gene
cassette (In994) were recovered from Chugoku region in 2004. ST357 isolates with blaIMP-11 group or ST235 with
blaIMP-7 emerged in 2006. We also report for the first time the presence of novel fosI gene cassette in strains other
than Mycobacterium spp.
Conclusions: Our data give an important “snapshot” of the molecular characteristics and dynamics of MBL-producing
lineages in P. aeruginosa in Japan. The significant association of specific genotypes and integrons implies that
dissemination and transmission of the preexisting resistant lineage, rather than horizontal gene transfer in situ,
might largely explain their endemicity.
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As carbapenems are among the most reliable therapeutic
options for treating Pseudomonas aeruginosa infection,
the finding of carbapenem resistance is an ominous de-
velopment that challenges this “last resort antibiotic”.
Production of metallo-β-lactamases (MBLs) is an im-
portant mechanism of carbapenem resistance, not only
because MBLs can hydrolyse most β-lactams including* Correspondence: yishii@med.toho-u.ac.jp
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unless otherwise stated.carbapenems, but MBL-producing P. aeruginosa are fre-
quently also multidrug-resistant (resistant to ≥ 3 classes)
[1]. More importantly, blaMBL genes are often located in
the gene cassette (GC) arrays in integrons, where mul-
tiple resistant determinants against antimicrobials or
disinfectants are accumulated, and can be horizontally
transferred [2].
Multilocus sequence typing (MLST), a genotyping
method based on nucleotide sequencing of several
house-keeping genes in the bacterial chromosome, has
been increasingly applied for epidemiological investiga-
tion of pathogenic microorganisms [3]. In P. aeruginosahis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Distribution of metallo-β-lactamase-producing
Pseudomonas aeruginosa across clinical specimens in the
present studya
Year of isolation
Clinical specimens ’04 ’06
Urinary tract 9/188 (0.9%) 15/220 (1.5%)
Respiratory tract 2/491 (0.2%) 2/449 (0.2%)
Gastrointestinal tract 1/33 (0.1%) 2/62 (0.2%)
Blood and fluids 2/73 (0.2%) 0/41 (0%)
Others 9/211 (0.9%) 2/220 (0.2%)
Total 23/996 (2.3%) 21/992 (2.1%)
ashown as a number of metallo-β-lactamase-producing P. aeruginosa isolates
divided by a number of all P. aeruginosa isolates.
Mano et al. BMC Microbiology  (2015) 15:41 Page 2 of 8isolates, international clones such as ST (sequence type)
235, ST244, ST175, and ST357 are reported to have
widespread dissemination [4-11]. Most notably, ST235
and their close variants (e.g., clonal complex 235) appear
prominent in multiple-drug resistance.
Recently, the INTEGRALL database was developed for
providing a systematic nomenclature for integrons [12];
these genetic elements can be potentially shared by a
wide range of microorganisms as a result of horizontal
gene transfer [13]. Moreover, GC arrays of integrons
could be excised or integrated by the action of integrases
and therefore be more diverse [2]. Therefore, INTE-
GRALL is expected to facilitate our comprehensive un-
derstanding of the complexity and development of
integron-mediated drug resistance.
In Japan, as many as 80-90% of the MBL-producing P.
aeruginosa were reported to be resistant to carbapen-
ems, aminoglycosides, and quinolones [14,15]. Notably,
several molecular epidemiological surveys report the in-
creasing prevalence of multidrug-resistant P. aeruginosa
(MDRP); in these the predominance of IMP-type MBL
genes as well as ST235 and ST357 among MDRP is
documented [15-20]. Although the prevalence of MBL
among P. aeruginosa clinical isolates was reported as 2-
4% [21,22], molecular epidemiology of MBL-producing
P. aeruginosa in consecutive nationwide surveillance
programs has not been analysed.
In the current study, we conducted a molecular epi-
demiological survey of the genetic context of MBL-
producing P. aeruginosa isolates collected by nationwide
surveillance. Our data not only provide an important
“snapshot” of the molecular characteristics and dynamics
of MBL-producing predominant lineages including
ST235 and ST357, but also provide important baseline
information for future surveillance programs. (This work
was presented in part at the 51st Interscience Conference
on Antimicrobial Agents and Chemotherapy, Chicago,
IL, 2011.)
Results and discussion
Antimicrobial susceptibility of MBL-producing
P. aeruginosa isolates
In the present study, 44 MBL-producing P. aeruginosa iso-
lates were identified (Table 1); these were recovered from 6
out of 8 geographic regions across Japan. The number of
isolates is comparable in 2004 and in 2006. MBL-
producers were isolated more frequently from urinary tract
specimens than from other specimens (24/408 vs. 20/1580;
P < 0.0001). Although this trend was consistent with the
previous reports in Japan [23], the reason for preference of
MBL-producers for urinary tract was not addressed in this
study where we did not analyse non-MBL-producers.
All MBL-producers met the international criteria for
MDRP (Table 2). Overall, the antibiotic resistancepatterns of MBL-producers did not differ significantly
among the isolates between 2004 and 2006, except in
cases where piperacillin was tested (4/23 resistant to
piperacillin in 2004 vs 16/21 in 2006; P = 0.0002). Al-
though this result reinforces the impact of the MBL
production in MDRP, their limited susceptibility to the
entire armamentarium of β-lactams including piperacil-
lin or aztreonam, which MBLs are expected to hydrolyse
less efficiently, suggests the involvement of multiple fac-
tors contributing to their drug resistance [24].
Acknowledging that CLSI breakpoints were not avail-
able, the majority of MBL-producers showed increased
susceptibility to arbekacin (MIC >8 μg/ml in only 5
strains, 11%). Although further investigation is needed,
this agent might be a candidate for consideration as a
therapeutic agent [25]. For more than two decades in
Japan, arbekacin is a commercially available aminoglyco-
side effective against methicillin-resistant Staphylococcus
aureus infections and its use in Gram negative infections
is being explored .
MBL genes and class 1 integrons among MBL-producing
P. aeruginosa
Among MBL-producing P. aeruginosa isolates, seven dif-
ferent MBL genes were identified. The most prevalent
was blaIMP-1 group found in 38 isolates (80%) (31
blaIMP-1, 5 blaIMP-10, and 2 blaIMP-6), followed by 3
blaIMP-7, 2 blaIMP-11 group (1 blaIMP-11 and 1 blaIMP-41),
and 1 blaVIM-1, as anticipated (Table 2) [15-19]. While
blaIMP-1 and blaIMP-10 were found both in 2004 and
2006, blaIMP-7, blaIMP-11, and blaIMP-41 emerged in 2006.
All MBL-producing isolates possessed intI1, and all
MBL genes were located in the GC arrays of class 1 inte-
gron (Table 2); 16 distinct MBL-harboring integrons
were identified. Complete GC arrays of all integrons ex-
cept one were successfully sequenced, as many as 13 of
which were novel to INTEGALL database. Fifteen iso-
lates harbored In113-like integrons, which consisted of 3
GCs, namely blaIMP-1 group cassette (blaIMP-1 in In113,
Table 2 Profiles of metallo-β-lactamase-producing Pseudomonas aeruginosa in this study
No. Year Location Specimens PFGE ST Integron MIC (μg/ml)
TUM No GC arrays PIPC CAZ CFPM AZT IPM AMK ABK CPFX
4046 2004 Shikoku Urine A 1070 In113 blaIMP-1 | aacA28 | aadA1 32 >512 >512 32 512 256 4 16
3986 2006 Kanto Urine C 235 (partial)a blaIMP-7
a 128 512 256 8 64 >512 32 16
3995 2006 Kanto Urine C 235 (partial)a blaIMP-7
a 256 >512 256 8 64 >512 64 16
3997 2006 Kanto Purulent discharge C 235 (partial)a blaIMP-7
a 8 >512 256 4 512 >512 64 32
3988 2006 Kinki Urine A 235 In113 blaIMP-1 | aacA28 | aadA1a 256 >512 >512 64 64 256 2 32
3977 2006 Hokkaido Feces B 235 In113 blaIMP-1 | aacA28 | aadA1a 256 512 512 64 128 256 2 32
3978 2006 Chugoku Drain B 235 In113 blaIMP-1 | aacA28 | aadA1a 256 512 256 16 64 256 4 32
3984 2006 Kanto Urine B 235 In113 blaIMP-1 | aacA28 | aadA1a 256 512 256 16 64 >512 2 >128
3989 2006 Chugoku Urine B 235 In113 blaIMP-1 | aacA28 | aadA1a 256 >512 >512 64 64 >512 4 32
3990 2006 Kanto Sputum B 235 In113 blaIMP-1 | aacA28 | aadA1a 128 >512 256 8 64 >512 4 >128
3991 2006 Kanto Urine B 235 In113 blaIMP-1 | aacA28 | aadA1a 256 512 256 8 64 >512 4 >128
3994 2006 Kanto Urine B 235 In113 blaIMP-1 | aacA28 | aadA1a 128 512 256 32 512 >512 2 32
4029 2004 Hokkaido Feces B 235 In113 blaIMP-1 | aacA28 | aadA1a 32 256 256 16 256 128 1 16
4034 2004 Kanto Purulent discharge B 235 In113 blaIMP-1 | aacA28 | aadA1a 128 >512 256 16 128 >512 4 16
4035 2004 Chugoku Urine B 235 In113 blaIMP-1 | aacA28 | aadA1a 512 >512 512 32 64 256 2 16
4031 2004 Kanto Purulent discharge B 235 In915 blaIMP-6 | aacA28 | aadA1a 64 128 128 16 >512 >512 4 32
3993 2006 Shikoku Urine B 235 In829 blaIMP-10 | aacA28 | aadA1a 16 >512 512 >512 256 128 2 >128
4036 2004 Kanto Urine B 235 In829 blaIMP-10 | aacA28 | aadA1a 256 >512 256 16 512 >512 4 32
3992 2006 Chugoku Urine D 357 In994 blaIMP-1 32 >512 >512 64 128 64 1 >128
4033 2004 Chugoku Urine D 357 In994 blaIMP-1 64 >512 >512 32 512 8 0.5 >128
4038 2004 Chugoku Purulent discharge D 357 In994 blaIMP-1 64 >512 >512 256 256 8 ≤0.25 32
4039 2004 Chugoku Urine D 357 In994 blaIMP-1 32 >512 >512 256 256 8 ≤0.25 64
4040 2004 Chugoku Urine D 357 In994 blaIMP-1 16 512 512 64 256 64 1 >128
4041 2004 Chugoku Purulent discharge D 357 In994 blaIMP-1 16 512 512 64 >512 256 1 >128
4042 2004 Chugoku Urine D 357 In994 blaIMP-1 16 512 512 32 256 64 1 >128
4043 2004 Chugoku Feces D 357 In994 blaIMP-1 16 512 512 32 >512 256 0.5 >128
4044 2004 Chugoku Sputum D 357 In994 blaIMP-1 32 512 512 64 >512 256 1 >128
4045 2004 Chugoku Urine D 357 In994 blaIMP-1 32 512 512 64 128 64 1 >128
3996 2006 Chugoku Pharyngeal mucus D 357 In995 blaIMP-10 8 >512 >512 32 256 64 1 >128
3979 2006 Shikoku Urine D 357 In826 aacA7 | fosI | blaIMP-41 | qacG 8 >512 512 8 256 256 8 >128
3985 2006 Kanto Feces D 357 In991 aacA7 | blaIMP-11 | blaOXA-2 | qacG 256 >512 256 8 64 128 2 16













Table 2 Profiles of metallo-β-lactamase-producing Pseudomonas aeruginosa in this study (Continued)
4047 2004 Kyusyu Purulent discharge F 244 In994 blaIMP-1 64 512 128 8 4 >512 32 >128
4048 2004 Kyusyu Purulent discharge F 244 In994 blaIMP-1 64 512 128 8 4 >512 32 >128
4037 2004 Kinki Urine F 244 In832 fosE | aacA31 | blaVIM-2 64 64 16 16 >512 256 1 16
3980 2006 Kyusyu Urine G 244 In993 blaIMP-10 | aadA2 | blaOXA-47b 128 >512 512 16 8 16 ≤0.25 32
4028 2004 Hokkaido Urine H 277 In994 blaIMP-1 512 >512 >512 64 256 16 0.5 >128
4030 2004 Hokkaido Urine H 277 In831 blaIMP-10 | aacA1, gcuG 16 >512 >512 64 >512 >512 8 32
4027 2004 Hokkaido Sputum I 186 In830 blaIMP-1 | aacA4′-3 | aacA1, gcuG | aadA1a 32 512 128 16 4 128 8 8
3981 2006 Kyusyu Urine J 175 In827 blaIMP-1 | aacA4′-3 | aacA4′-3 | catB6 | blaCARB-12 512 >512 >512 128 256 128 4 >128
3982 2006 Kyusyu Urine J 175 In827 blaIMP-1 | aacA4′-3 | aacA4′-3 | catB6 | blaCARB-12 >512 >512 >512 128 256 64 4 32
3983 2006 Kyusyu Urine J 175 In827 blaIMP-1 | aacA4′-3 | aacA4′-3 | catB6 | blaCARB-12 512 >512 >512 128 256 64 8 32
4032 2004 Kanto Blood J 308 In992 aacA7 | blaIMP-1 16 >512 512 16 256 32 0.5 8
3987 2006 Kyusyu Urine K 360 In828 blaIMP-1 | aadA24, aacA4′-3 128 256 128 32 64 128 2 32
PFGE, pulsed-field gel electrophoresis; ST, sequence type; PIPC, piperacillin; CAZ, ceftazidime; CFPM, cefepime; AZT, aztreonam; IPM, imipenem; AMK, amikacin; ABK, arbekacin; CPFX, ciprofloxacin.
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aacA28 and aacA1a GCs. Similarly, thirteen isolates har-
bored In994-like integrons which contains a sole blaIMP-1
group cassette (blaIMP-1 in In994 and blaIMP-10 in In995).
The family of blaMBL genes and their position in integron
GC arrays did not show significant differences in resist-
ance profile (Table 2).
Genotypes and their relationship with integrons among
MBL-producing P. aeruginosa
Among MBL-producing P. aeruginosa isolates, nine dif-
ferent STs were identified by MLST: the most prevalent
was ST235 (17 isolates, 39%) followed by ST357 (14 iso-
lates, 32%) and ST244 (4 isolates, 9%) (Table 2). While
these major 3 STs were found both in 2004 and 2006,
the other 6 STs were found either in 2004 or in 2006.
Most integrons distributed in the specific genotypes of
the isolates. In113-like integrons were found in ST235/
pulsotype B isolates with significantly high frequency
(13/13 vs 2/31; P < 0.0001), while partial blaIMP-7-harboring
integron was exclusively found in ST235/pulsotype C (3/3
vs 0/41; P < 0.0001). While distributed across 5 geographic
regions in total, ST235 was significantly associated with
Kanto region (10/12 vs 7/32; P = 0.0003). ST235 was also
associated with resistance to piperacillin (13/17 vs 7/27;
P = 0.0017). Although not significant, a trend of increased
ST235 in 2006 was observed (5/23 in 2004 vs 12/21 in
2006; P = 0.0291).
MBL-producing ST235 isolates seemed the dominant
MDRP lineage in Japan as also reported worldwide
[6,8-11,13]. As ST235 isolates are described as harboring
a variety of resistance determinants including integrons,
its diverse geographic distribution across Japan reflects
part of the worldwide dissemination. Especially, isolates of
ST235/pulsotype B with In113-like integron, recovered
from 3 regions in the present study, were well character-
ized as a representative of the MDRP in Japan [15,16,19].
In our analysis, ST357 was significantly associated with
In994-like integrons (11/14 vs. 3/30, P < 0.0001). ST357
is another widely disseminated lineage also found in the
present study [4,7,16]. Concurrently, ST357 was found
in Chugoku region with significantly higher frequency
(11/14 vs 3/30, P < 0.0001), which might possibly reflect
local transmission. However, ST357 harbored 5 different
integrons in total, including 2 with blaIMP-11 group GCs
emerged in 2006 (In826 and In991).
The significant association of specific genotypes and
integrons implies that, in a relatively short period of
time, dissemination and transmission of the preexisting
resistant lineage, rather than horizontal gene transfer or
recombination in situ, might largely explain their en-
demicity. Moreover, the genotypes of MBL-producers
were unexpectedly similar to those in the central Europe
with different resistant determinants, suggesting theirpossible advantage beyond other genotypes in the clin-
ical settings [4]. Although the isolate number was small,
the present study elucidated the emergence of ST357
isolates with novel integrons in distant geographic re-
gions in 2006, as well as an emergence of the ST235/
pulsotype C with partial integron harboring blaIMP-7 in
Kanto region, which might suggest the increased com-
plexity of endemic lineages. In addition, isolates with
ST175 was recovered in Kyushu with significantly higher
frequency (3/3 vs 5/41, P = 0.0042).
One of the limitations of the present study is that this
is retrospective in nature and therefore the results are
not expected to be directly applied to the current clinical
situation. There are also several reports in Japan ad-
dressing a variety of integron structures of P. aeruginosa
[15-20], and they seemed to contain identical or similar
integrons to ones identified in the current study. Never-
theless, the findings here are important, since most of
the integron structures were novel to INTEGRALL data-
base [12]; this could be explained by the lack of compre-
hensive platform for integron structure and nomenclature
before the development of INTEGRALL database until
recently. Alternatively, this might reflect true heterogen-
eity and diversity of the integrons among clinical isolates,
especially among non-predominant lineages. Moreover,
MLST comparison of cross-sectional nationwide survey is
much informative for understanding of the dynamics of
drug-resistant organisms. In addition, this is the first re-
port of the presence of novel fosI gene cassette other than
Mycobacterium spp. [26], and further analysis regarding
the actual transfer route beyond the boundary of the spe-
cies is warranted. As genotyping including MLST and
INTEGRALL has been increasingly applied for tracking
the development of the drug resistance rationally, the data
in the present study would provide a robust baseline to es-
timate the current trend and future diversification of the
drug-resistant lineages [20]. Another shortcoming of this
study is that horizontal gene transfer of blaMLB genes,
possibly located on plasmid or chromosome, was not ex-
perimentally addressed.
Conclusions
The current study offers an important “snapshot” of the
molecular characteristics and dynamics of MBL-producing
P. aeruginosa lineages including ST235 and ST357 across
Japan and provide critical information for the design and
implementation of surveillance programs targeted to the
discovery of multidrug resistant P. aeruginosa.
Methods
Bacterial isolates
A total of 1,988 P. aeruginosa isolates (996 isolates in
2004 and 992 in 2006), were retrospectively collected as
a part of nationwide surveillance programs in Japan
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Group) [27,28]. Briefly, up to 10 non-duplicated patient
isolates of 10 organism groups including P. aeruginosa
were collected for three months in 2004 and in 2006 from
a total of 100 institutions in 8 geographic regions. MBL-
producers were phenotypically identified by the double-
disk synergy test using ceftazidime (30 μg) and sodium
mercaptoacetate (30 μg) disks (Eiken Chemical, Inc.,
Tokyo, Japan) following the manufacturer’s instructions,
and were subjected to further molecular epidemio-
logical investigation [29]. Ethical approval has been ob-
tained from Toho University School of Medicine Ethics
Committee (2511925030).
Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) were mea-
sured by the broth microdilution method of the Clinical
and Laboratory Standards Institute (CLSI) [30]. The
antimicrobial agents tested were as follows: piperacillin
sodium salt, ceftazidime hydrate, aztreonam, imipenem
monohydrate, amikacin sulfate salt, ciprofloxacin hydro-
chloride monohydrate (Sigma-Aldrich Japan KK., Tokyo,
Japan), cefepime hydrochloride (Bristol-Myers Squibb.
Tokyo, Japan), and arbekacin sulfate salt (Meiji Seika
Pharma Co., Ltd. Tokyo, Japan). The antimicrobial con-
centration ranges were 0.06 - 128 μg/ml except for cip-
rofloxacin (0.25 - 512 μg/ml). MICs were interpreted as
susceptible (S), intermediate (I), or resistant (R) accord-
ing to CLSI interpretive criteria where available [31].
MDRP was defined as strains with non-susceptibility
to at least 1 agent in ≥3 antimicrobial categories accord-
ing to the international expert proposal [32]; amikacin as
aminoglycosides, imipenem as antipseudomonal carba-
penems, ceftazidime or cefepime as antipseudomonal
cephalosporins, aztreonam as monobactams.
Analysis of MBL genes and integron by PCR amplification
and nucleotide sequencing
Genomic DNA was prepared by the Wizard genomic
DNA preparation kit (Promega, Madison, WI, USA) ac-
cording to the manufacturer’s recommendations. PCR
was performed with Takara ExTaq (Takara Bio, Shiga,
Japan). Nucleotide sequencing was performed by a com-
mercial DNA sequencing service (Greiner Bio-one, Tokyo,
Japan).
blaMBL genes were detected and identified by PCR and
nucleotide sequencing using primers for blaIMP and
blaVIM [33]. blaIMP-1, blaIMP-10, and blaIMP-6 are referred
as blaIMP-1 group because the deduced amino acid se-
quences of blaIMP-1 differ by single amino acid from
those of blaIMP-10 and blaIMP-6. Similarly, blaIMP-11 and
blaIMP-41 are as blaIMP-11 group because the deduced
amino acid sequences differ by single amino acid. Inte-
grase genes specific for class 1, 2, or 3 integrons weredetected by PCR using primers by Shibata et al. [33].
Integron GC arrays were determined by PCR and nu-
cleotide sequencing by primer walking [34]. According
to INTEGRALL nomenclature, novel completely se-
quenced GCs, namely from a part of 5′-conserved seg-
ment (5′CS) to a part of 3′-conserved segment (3’CS),
were submitted to INTEGRALL for the attribution of
new integron numbers [12].
Genotyping
MLST was performed as described by Curran et al. [3].
Pulsed-field gel electrophoresis (PFGE) of SpeI-digested
DNA fragments from each strain was performed on a
CHEF-MAPPER II apparatus (Bio Rad Laboratories,
Rockland, Maine, USA) at 6 V/cm, for 19.7 h with pulse
times running from 5.3 to 34.9 s in 0.5 × TBE buffer at
14°C. PFGE patterns in the dendrogram were analyzed
with Molecular Analyst Software Fingerprinting II (Bio-
Rad Laboratories). Only restriction fragments larger than
50 kb were used for analysis. PFGE genotypes were dis-
tinguished by the unweighted pair-group method using
average linkages (UPGMA) and Dice coefficient, and iso-
lates with ≥80% similarity were assigned into the same
pulsotype.
Statistical analyses
Statistical calculations were made using Graph-Pad
Prism 5.01 (GraphPad Software Inc.). P values were cal-
culated from two-tailed Fisher’s exact test for categorical
variables, and P value <0.01 was considered as a statisti-
cally significant difference.
Nucleotide sequences accession numbers for novel
integrons
Genbank/EMBL/DDBJ accession numbers for novel nu-
cleotide sequences in the present study are as follows:
AB901034-AB901041 for In826-In833, and AB901042-
AB901046 for In991-995, and AB901047 for partial inte-
gron of isolate TUM3995.
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